Vulva Cancer Market Headed for Growth and Global Expansion by 2025

Vulva Cancer Market Headed for Growth and Global Expansion by 2025
Vulva cancer is rare type of cancer which forms in a woman’s external genitalia called the vulva.
The vulva is an area of the skin that surrounds the vagina and urethra, including mons pubis,
perineum, labia, bartholin glands, and clitoris. The labia majora is the most common site to develop
vulva cancer. The cancer can occur at any age but primarily affects older women over the age of 65
years. Symptoms of the cancer include pain, itching, bleeding in between menstruation cycle, and
tenderness. It often forms lump or sore. Women who are infected with human papillomavirus
(HPV) are at a higher risk of developing vulva cancer. Although the most common cause is viral
infection, but factors such as smoking, diabetes, hypertension, immune system deficiency, lichen
sclerosus, and presence of precancerous conditions such as vulvar intraepithelial neoplasia, increase
the risk of vulva cancer. Vulva cancer is the fourth most common gynecologic cancer comprising of
4.7% of malignant neoplasms in the genital tract.
Report Overview and TOC @ https://www.transparencymarketresearch.com/vulva-cancermarket.html
Based on predisposing factor, the vulva cancer market is segmented as human papillomavirusassociated vulva cancer and human papillomavirus unassociated vulva cancer. The human
papillomavirus-associated vulva cancer segment is expected to grow as 50%-75% of vulva cancer
cases are due to human papillomavirus infection. Based on type, the market is classified as
squamous cell carcinoma, adenocarcinoma, basal cell carcinoma, vulvar melanoma, and vulvar
sarcoma. The squamous cell carcinoma segment is projected to grow as 95% of the vulvar cancer
are squamous cell carcinoma, followed by melanoma and sarcoma. Based on treatment, the market
is segmented as surgery, radiation, and chemotherapy. The surgery segment includes laser surgery,
vulvectomy, pelvic exenteration, and excision.
Request brochure @ https://www.transparencymarketresearch.com/sample/sample.php?
flag=B&rep_id=26603
The chemotherapy segment involves the use of drugs that kill and control the growth of cancerous
cell. Chemotherapy may also include monotherapy or a combination of two or more drugs
depending upon the type of cancer and rate of progression. The chemotherapy segment is expected
to grow due to the development of new molecules such as nivolumab by Bristol-Myers Squibb
Company for the treatment of vulva cancer. Increase in incidence rate, development of new
therapies such as biologics, burden of human papillomavirus infection in women, increase in
incidence of sexually transmitted diseases, and less surveillance rate are the factors boosting the
growth of the vulva cancer market. However, high cost of therapy and side effects associated with it
are factors hampering the growth of the vulva cancer market.
Geographically, the vulva cancer market is dominated by North America, followed by Europe, due
to increase in incidence rate, rise in geriatric population, and growth in research and development
expenditure. Asia Pacific is an emerging market due to the developing health care infrastructure,
increase in incidence rate, and rising government expenditure in the health care industry. Factors
such as rising awareness about vulva cancer and improving economy are driving the vulva cancer
market in Middle East & Africa. However, high cost of therapy and lack of proper treatment are
restraining the growth of the Middle East & Africa market.
Key players operating in the vulva cancer market include ISA Pharmaceuticals B.V., Ono
Pharmaceutical Co., Ltd., ORYX GmbH & Co. KG, F. Hoffmann-La Roche Ltd, Celgene
Corporation, Bristol-Myers Squibb Company, Johnson & Johnson, PDS Biotechnology
Corporation, Novartis AG, Merck & Co., Pfizer Inc., and Amgen Inc.
Pre Book full report@ https://www.transparencymarketresearch.com/checkout.php?
rep_id=26852&ltype=S
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative
insights, historical data, and verifiable projections about market size. The projections featured in the
report have been derived using proven research methodologies and assumptions. By doing so, the
research report serves as a repository of analysis and information for every facet of the market,
including but not limited to: Regional markets, technology, types, and applications.
About TMR
Transparency Market Research (TMR) is a global market intelligence company providing business
information reports and services. The company’s exclusive blend of quantitative forecasting and
trend analysis provides forward-looking insight for thousands of decision makers. TMR’s
experienced team of analysts, researchers, and consultants use proprietary data sources and various
tools and techniques to gather and analyze information.
Contact
Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com
TMR Blog: http://www.theglobalhealthnews.com/

Download Report